[The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus].

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Kardiologia polska

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 20648456
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review

  2025influential citation
• Triglycerides, Glucose Metabolism, and Type 2 Diabetes

  2025cites this paper
• Remnant Cholesterol: From Pathophysiology to Clinical Implications in Type 1 Diabetes

  2025cites this paper
• The Association of Fibrate Use with Kidney Outcomes and Mortality

  2025cites this paper
• Discordance Analysis of VLDL-C and ApoB in UK Biobank and Framingham Study: A Prospective Observational Study

  2024cites this paper
• Modulatory effect of aqueous leaf extract of Terminalia catappa on dyslipidemia in alloxan induced diabetic rats

  2024cites this paper
• Ultra-Processed Food Intake and Increased Risk of Obesity: A Narrative Review

  2024cites this paper
• Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia

  2024cites this paper
• Dyslipidemia: A Narrative Review on Pharmacotherapy

  2024cites this paper
• Non-Fasting Plasma Triglycerides Are Positively Associated with Diabetes Mortality in a Representative US Adult Population

  2024cites this paper
• Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia

  2024cites this paper
• Effect of transgenerational diabetes via maternal lineage in female rats

  2024cites this paper
• Importance of Dyslipidaemia Treatment in Individuals with Type 2 Diabetes Mellitus—A Narrative Review

  2023cites this paper
• Medical Management of Peripheral Artery Disease

  2023cites this paper
• Identification of a Common Variant for Coronary Heart Disease at PDE1A Contributes to Individualized Treatment Goals and Risk Stratification of Cardiovascular Complications in Chinese Patients With Type 2 Diabetes

  2023cites this paper
• Management of Dyslipidemia in Patients with Diabetes Mellitus

  2023cites this paper
• Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans

  2023cites this paper
• Can Concurrent Fibrate Use Reduce Cardiovascular Risks among Moderate Chronic Kidney Disease Patients Undergoing Statin Therapy? A Cohort Study

  2023cites this paper
• Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence

  2023cites this paper
• Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

  2022cites this paper
• The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol

  2022cites this paper
• Decoding microRNA drivers in atherosclerosis

  2022cites this paper
• Improvement of clinical outcomes in patients undergoing peritoneal dialysis using hydroxymethylglutaryl-CoA reductase inhibitors: A systematic review and meta-analysis

  2022cites this paper
• Manejo do risco cardiovascular: dislipidemia

  2021cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.

  2021influential citation
• Novel biomarker panel measuring endothelial injury identifies patients at risk of coronary artery syndrome and discordance with low-density lipoprotein cholesterol

  2021cites this paper
• Relations between Interlukin-6 and Some Biochemical Parameters in Diabetic Foot Syndrome

  2021cites this paper
• New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation.

  2021cites this paper
• Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials.

  2021cites this paper
• The Efficacy and Safety of Chinese Medicine Fufang Zhenzhu Tiaozhi Capsule (FTZ) in the Treatment of Diabetic Coronary Heart Disease: Study Protocol for Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2021cites this paper
• Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

  2021cites this paper
• Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014

  2020cites this paper
• Japanese Clinical Practice Guideline for Diabetes 2019

  2020cites this paper
• Diabetes in Older Adults

  2020cites this paper
• Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial

  2020cites this paper
• Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association.

  2020cites this paper
• Evaluating the effectiveness of a support programme for people with type 2 diabetes mellitus in primary care: an observational prospective study in Ecuador

  2020cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021.

  2020cites this paper
• A Mendelian Randomization Study Provides Evidence That Adiposity and Dyslipidemia Lead to Lower Urinary Albumin-to-Creatinine Ratio, a Marker of Microvascular Function

  2020cites this paper
• Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline

  2020cites this paper
• Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors

  2020cites this paper
• Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.

  2020cites this paper
• The Rise and Fall “ing” of the HDL Hypothesis

  2020cites this paper
• Cardiovascular Disease in Women: Focus on Lipid Management

  2020cites this paper
• Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2

  2020cites this paper
• Exercise based assessment of cardiac autonomic function in type 1 versus type 2 diabetes mellitus

  2020cites this paper
• Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society.

  2020cites this paper
• Documento de consenso de un grupo de expertos de la Sociedad Española de Arteriosclerosis (SEA) sobre el uso clínico de la resonancia magnética nuclear en el estudio del metabolismo lipoproteico (Liposcale)

  2020cites this paper
• Fenofibrate prevents iron induced activation of canonical Wnt/β-catenin and oxidative stress signaling in the retina

  2020cites this paper
• PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid

  2020influential citation
• Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab

  2020cites this paper
• Management of hypertriglyceridemia

  2020cites this paper
• Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT

  2019cites this paper
• Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes

  2019cites this paper
• Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2019)

  2019cites this paper
• Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.

  2019cites this paper
• VHRM_A_209830 149..157

  2019cites this paper
• Awareness and knowledge of Diabetic retinopathy among Diabetic patients in a tertiary care hospital of western Odisha, India

  2019cites this paper
• Low-dose phloretin alleviates diabetic atherosclerosis through endothelial KLF2 restoration

  2019cites this paper
• Leveraging Genetics to Improve Cardiovascular Health in Diabetes: The 2018 Edwin Bierman Award Lecture

  2019cites this paper
• Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study

  2019cites this paper
• Diabetes and Cardiovascular Disease

  2019cites this paper
• Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

  2019cites this paper
• Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.

  2019cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

  2019cites this paper
• Diagnosis and Management of Dyslipidemia

  2019cites this paper
• High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus

  2019cites this paper
• Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?

  2019cites this paper
• Prevención primaria de la enfermedad cardiovascular en la diabetes mellitus

  2018cites this paper
• Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2

  2018cites this paper
• Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes

  2018cites this paper
• Therapie der diabetischen Dyslipidämie

  2018cites this paper
• Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

  2018cites this paper
• [Salvation of the diabetic foot through a comprehensive individualized treatment of the patient with type 2 diabetes: case study].

  2018cites this paper
• Effect of Serial Infusions of CER-001, a Pre-&bgr; High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial

  2018cites this paper
• Fenofibrate and Dyslipidemia: Still a Place in Therapy?

  2018cites this paper
• Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.

  2018cites this paper
• 28 – Primary Prevention of Atherosclerotic Cardiovascular Disease

  2018cites this paper
• Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care

  2018cites this paper
• Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver

  2018cites this paper
• Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association.

  2018cites this paper
• [A near future of treatment of dyslipidemia in type 2 diabetics].

  2018cites this paper
• Combined lipid-lowering therapy.

  2018influential citation
• PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option

  2018cites this paper
• Ophthalmic and clinical factors that predict four-year development and worsening of diabetic retinopathy in type 1 diabetes.

  2018cites this paper
• [Randomized, controlled clinical trials with observational follow-up investigations for evaluating efficacy of antihyperglycaemic treatment. I. Main results of the studies].

  2018cites this paper
• The pharmacological management of metabolic syndrome

  2018cites this paper
• Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018

  2018cites this paper
• Cardiovascular Disease and Risk Management : Standards of Medical Care in Diabetes d 2019

  2018cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019

  2018cites this paper
• Top 20 POEMs of the Past 20 Years: A Survey of Practice-Changing Research for Family Physicians

  2018cites this paper
• Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial

  2018cites this paper
• Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

  2018cites this paper
• PCSK9 as a therapeutic target for cardiovascular disease

  2017cites this paper
• Cardiovascular Disease and Diabetes: Two Sides of the Same Coin!

  2017cites this paper
• Statin Intolerance: Diagnosis and Management

  2017cites this paper
• Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes

  2017cites this paper
• Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.

  2017cites this paper
• Hypertriglyceridemia : A Practical Review Artical for Assessment and Treatment

  2017cites this paper
• The effects of PPARα and PPARγ agonists on proteinuria and oxidative stress in patients with type 2 diabetes mellitus

  2017cites this paper